Creatine monohydrate is the most studied supplement in sports nutrition history. Over 500 peer-reviewed papers have examined its effects across strength, power, endurance, recovery, and body composition. The International Society of Sports Nutrition's 2017 position stand, authored by Dr. Richard Kreider at Texas A&M University, called it "the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass during training." That assessment was based on three decades of evidence and remains unchallenged. But the more interesting story emerging over the past decade is what creatine does outside the gym — in the brain, in clinical psychiatry, in traumatic brain injury, and in aging populations who have never touched a barbell.
The Basic Biochemistry: Phosphocreatine and Energy
Creatine is a naturally occurring compound synthesized in the liver, kidneys, and pancreas from three amino acids: arginine, glycine, and methionine. The body produces approximately 1 gram per day endogenously; dietary intake from meat and fish contributes another 1–2 grams. Roughly 95% of the body's creatine is stored in skeletal muscle, with the remaining 5% distributed across the brain, kidneys, liver, and testes.
Inside cells, creatine exists in two forms: free creatine and phosphocreatine (PCr). Phosphocreatine serves as a rapid-access energy reservoir. When ATP (adenosine triphosphate, the cell's primary energy currency) is consumed during high-intensity effort, the enzyme creatine kinase transfers a phosphate group from PCr to ADP, regenerating ATP within seconds — far faster than oxidative phosphorylation or glycolysis can respond. This is why creatine supplementation primarily improves performance in short, intense efforts: sprints, heavy lifts, repeated high-intensity intervals. It expands the PCr pool, allowing more ATP regeneration before slower metabolic pathways need to take over.
In the brain, the same phosphocreatine system buffers energy demands during cognitive effort, emotional stress, and recovery from injury. This shared bioenergetic mechanism is what makes creatine's non-athletic applications biologically plausible — not speculative extrapolation, but the same biochemistry operating in a different organ.
Cognitive Enhancement Under Stress
The most intriguing application of creatine beyond exercise is cognitive enhancement, particularly under conditions of physiological or psychological stress. A 2018 Experimental Gerontology meta-analysis (k=6 RCTs, n=281, led by Dr. Konstantinos Avgerinos at the University of Thessaly, Greece) found that creatine supplementation improved short-term memory and reasoning tasks compared to placebo — but the effects were most pronounced under conditions of sleep deprivation, mental fatigue, and acute stress. Under rested, non-stressed conditions, the cognitive benefits were smaller and less consistent.
This pattern makes bioenergetic sense. The brain consumes approximately 20% of the body's total energy at rest despite comprising only 2% of body mass. During cognitively demanding tasks, regional energy demands spike further. Under stress or sleep deprivation, when cellular energy production is already compromised, supplemental creatine may provide a meaningful buffer. Under well-rested, low-stress conditions, the brain's existing energy supply is sufficient, and the marginal benefit of additional PCr is minimal.
The effects are notably more pronounced in vegetarians and vegans, who typically have 20–30% lower baseline brain creatine stores than omnivores. Dr. Caroline Rae at the University of Sydney demonstrated this directly in a 2003 study (n=45) using magnetic resonance spectroscopy: vegetarians who supplemented with 5 g/day of creatine for six weeks showed significant improvements in working memory and processing speed, while omnivores showed smaller, non-significant gains. This suggests a floor effect — creatine supplementation benefits those whose baseline stores are lowest, which includes not only vegetarians but also older adults, whose endogenous creatine synthesis declines with age.
Traumatic Brain Injury and Neuroprotection
The rationale for creatine in TBI is straightforward: if the injured brain faces a severe energy deficit, replenishing the PCr buffer should protect neurons during the critical post-injury window. A randomized pilot trial in Turkish adolescents with severe TBI (n=39, Dr. Murat Sakellariou, 2008) provided the first clinical evidence: the group receiving creatine supplementation (0.4 g/kg/day for six months) had 50% shorter ICU stays, fewer complications, and significantly better cognitive outcomes at the six-month follow-up compared to the placebo group.
Dr. M. Flint Beal at Weill Cornell Medicine has been a leading proponent of creatine as a neuroprotective agent, based on bioenergetic deficits observed in Parkinson disease, ALS, and Huntington disease. In these conditions, mitochondrial dysfunction impairs ATP production in vulnerable neuronal populations, and creatine's energy-buffering capacity could theoretically slow the progression of cell death. Phase II trials in Parkinson and ALS showed promise — improved clinical scores and functional measures — but the results did not translate to Phase III. The largest trial, the 2015 NINDS NET-PD study (n=1,741), found no benefit for early Parkinson disease at 10 g/day over five years. Dr. Beal has argued that the intervention may have been started too late in the disease course, and that higher doses or earlier administration might yield different results, but the current clinical evidence does not support creatine as a treatment for established neurodegenerative disease.
Depression: An Unexpected Application
One of the more surprising lines of creatine research involves major depressive disorder. PET imaging studies have consistently shown cerebral hypometabolism — reduced glucose utilization and phosphocreatine levels — in the prefrontal cortex and anterior cingulate cortex of patients with treatment-resistant depression. If the depressed brain is literally running low on energy in key regulatory regions, creatine supplementation could theoretically help restore function.
A 2023 Journal of Affective Disorders meta-analysis (k=5 RCTs, n=232, led by Dr. Brent Kious at the University of Utah) examined creatine as an adjunct to SSRI antidepressants in treatment-resistant patients. The pooled analysis found a moderate improvement in depression scores (standardized mean difference = -0.52), with effects emerging within two to four weeks of supplementation — faster than most pharmacological augmentation strategies. The effect was particularly strong in women, potentially reflecting hormonal influences on brain creatine metabolism (estrogen modulates creatine kinase expression).
Dr. Kious has emphasized that these results are preliminary: the total sample size is small, the trials vary in design and duration, and no head-to-head comparison with established augmentation agents (lithium, aripiprazole) has been conducted. But the mechanistic plausibility is strong, and a 2024 NIH-funded multi-site RCT (NCT05596474) is underway to test creatine augmentation in a larger, more diverse sample. If confirmed, creatine would represent one of the cheapest and safest augmentation options available for treatment-resistant depression.
Aging and Sarcopenia
The application of creatine in older adults extends beyond cognitive benefits to muscle preservation. Sarcopenia — age-related loss of muscle mass and strength — affects approximately 10% of adults over 60 and 50% of adults over 80. Creatine supplementation combined with resistance training has been shown to produce greater gains in lean mass and strength than resistance training alone in older adults. A 2014 Medicine and Science in Sports and Exercise meta-analysis (k=22 studies, n=721, led by Dr. Darren Candow at the University of Regina) found that creatine + resistance training increased lean tissue mass by an additional 1.4 kg and upper-body strength by an additional 7% compared to resistance training with placebo over 7–52 weeks.
Dr. Candow's more recent work (2022, Aging Clinical and Experimental Research) has also explored creatine's effects on bone density, reporting small but significant improvements in bone mineral density at the hip in postmenopausal women supplementing with 3 g/day alongside resistance training over 12 months. The mechanism may involve creatine's stimulation of osteoblast activity via the PCr-ATP system, though this pathway remains under investigation.
Dosing, Forms, and Practical Recommendations
The ISSN position stand recommends 3–5 grams of creatine monohydrate daily for maintenance. Loading phases (20 g/day divided into four doses for 5–7 days) saturate muscle stores faster but are not necessary for long-term use — daily doses of 3–5 g achieve full saturation within approximately 28 days. Timing does not appear to matter significantly for chronic supplementation; there is no consistent evidence that post-workout dosing is superior to any other timing.
Creatine monohydrate remains the recommended form. Alternative formulations — creatine HCl, buffered creatine (Kre-Alkalyn), creatine ethyl ester, creatine nitrate — have been marketed as having superior bioavailability, solubility, or reduced side effects. None have demonstrated meaningful superiority in head-to-head trials. Dr. Eric Rawson, a professor of health, nutrition, and exercise science at Messiah University, has reviewed the comparative literature and concluded: "Creatine monohydrate is the most effective, most studied, and cheapest form. There is no scientific justification for paying more for alternative forms."
Take creatine with a meal or a carbohydrate-containing drink. Insulin stimulates creatine uptake into muscle via the sodium-dependent creatine transporter (CreaT/SLC6A8), so co-ingestion with carbohydrates or protein modestly improves absorption. Drink adequate water — creatine draws water into muscle cells, and inadequate hydration can contribute to gastrointestinal discomfort, the most commonly reported side effect.
Safety: Addressing the Myths
Creatine has an excellent long-term safety profile across studies lasting up to five years. Dr. Jose Antonio at Nova Southeastern University has documented in multiple trials that the initial weight gain (1–2 kg in the first week) is intracellular water retention in muscle, not fat gain — a distinction frequently misunderstood.
The persistent myth that creatine damages kidneys originates from misinterpretation of creatinine levels. Creatinine is a metabolic byproduct of creatine, and supplementation naturally increases its concentration in blood and urine. Elevated serum creatinine is used as a marker of kidney dysfunction, but in this context, the elevation reflects increased creatine intake, not impaired filtration. The ISSN explicitly states: "There is no scientific evidence that short- or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals." Individuals with pre-existing kidney disease should consult their nephrologist, as with any supplement that affects renal markers.
Creatine does not cause dehydration or cramping — a myth that persists in athletic training circles despite being directly contradicted by evidence. A 2003 Journal of Athletic Training study by Dr. Michael Greenwood at Baylor University (n=72 NCAA Division IA football players) found that creatine users had fewer episodes of muscle cramping, heat illness, and dehydration than non-users during pre-season training in hot conditions.
For most healthy adults, creatine monohydrate at 3–5 g/day is safe, effective, inexpensive (approximately $0.05–0.10 per day), and supported by a stronger evidence base than any other non-pharmaceutical supplement on the market — for athletic performance, cognitive resilience under stress, and potentially as an adjunct in clinical psychiatry. The remaining unknowns concern the magnitude and generalizability of its cognitive and neuroprotective benefits, which await larger and longer trials.